China Clarifies Position on Forged Trial Data As 30 Applications Are Rejected
Executive Summary
As more new drug applications get rejected under the China Food and Drug Administration’s drive to stamp out trial data forgery, the regulator has issued draft guidance to clarify its position on data integrity breaches.
You may also be interested in...
China Probe Reveals Widespread Drug Data Violations At Major Study Centers
Severe adverse events left unreported, critical data gone missing, subject drugs substituted to pass bioequivalent testing - these are just some of the wrongdoings disclosed by the China Food and Drug Administration in a rare report on regulatory transgressions during drug trials conducted in the country.
Chinese regulator surprises pharma with clinical data self-audit notice
A China Food and Drug Administration announcement released on July 22 is requiring the drug applicants in over 1,600 pending product approvals to conduct self-audits of the clinical data and submit an electronic version of the reports to the CFDA’s Center for Drug and Food Inspection1.
Kite Strikes CAR-T Access & Discount Deal For Tecartus In England
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: